MXPA05013974A - Formulaciones farmaceuticas de compuestos de inhibicion amiloidea. - Google Patents

Formulaciones farmaceuticas de compuestos de inhibicion amiloidea.

Info

Publication number
MXPA05013974A
MXPA05013974A MXPA05013974A MXPA05013974A MXPA05013974A MX PA05013974 A MXPA05013974 A MX PA05013974A MX PA05013974 A MXPA05013974 A MX PA05013974A MX PA05013974 A MXPA05013974 A MX PA05013974A MX PA05013974 A MXPA05013974 A MX PA05013974A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
inhibiting compounds
amyloid
amyloid inhibiting
methods
Prior art date
Application number
MXPA05013974A
Other languages
English (en)
Inventor
Audley Legore
Original Assignee
Neurochem Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Int Ltd filed Critical Neurochem Int Ltd
Publication of MXPA05013974A publication Critical patent/MXPA05013974A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formulaciones y metodos terapeuticos para inhibir deposicion de amiloide en un sujeto, cualquiera que sea su situacion clinica. Las formulaciones y metodos terapeuticos para prevenir o tratar amiloidosis y/o enfermedad relacionada con amiloide se describen tambien.
MXPA05013974A 2003-06-23 2004-06-21 Formulaciones farmaceuticas de compuestos de inhibicion amiloidea. MXPA05013974A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48098403P 2003-06-23 2003-06-23
US51211603P 2003-10-17 2003-10-17
US10/871,549 US20050142191A1 (en) 2003-06-23 2004-06-18 Pharmaceutical formulations of amyloid inhibiting compounds
PCT/IB2004/002381 WO2004112762A2 (en) 2003-06-23 2004-06-21 Pharmaceutical formulations of amyloid inhibiting compounds

Publications (1)

Publication Number Publication Date
MXPA05013974A true MXPA05013974A (es) 2006-03-09

Family

ID=33545348

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013974A MXPA05013974A (es) 2003-06-23 2004-06-21 Formulaciones farmaceuticas de compuestos de inhibicion amiloidea.

Country Status (18)

Country Link
US (2) US20050142191A1 (es)
EP (2) EP2127648A1 (es)
JP (1) JP4903561B2 (es)
CN (1) CN103550196A (es)
AT (1) ATE438391T1 (es)
AU (2) AU2004248995B2 (es)
BR (1) BRPI0411808A (es)
CA (1) CA2529268C (es)
DE (1) DE602004022408D1 (es)
DK (1) DK1635799T3 (es)
ES (1) ES2328818T3 (es)
IL (1) IL172193A0 (es)
MX (1) MXPA05013974A (es)
NZ (1) NZ544685A (es)
PL (1) PL1635799T3 (es)
PT (1) PT1635799E (es)
SI (1) SI1635799T1 (es)
WO (1) WO2004112762A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282400A (en) * 1999-04-28 2000-11-10 Neurochem (International) Limited Compositions and methods for treating amyloidosis
WO2001003680A2 (en) * 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
EP1585520A1 (en) * 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2007069073A2 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US20070049638A1 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
PL3851447T3 (pl) 2006-10-12 2024-03-04 Bellus Health Inc. Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
CN101730529A (zh) * 2006-12-22 2010-06-09 贝鲁斯健康(国际)有限公司 用于治疗代谢疾病和糖尿病的方法、化合物和组合物
CA2727019A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
WO2010040232A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
US9735792B2 (en) 2013-01-08 2017-08-15 Rambus Inc. Integrated circuit comprising circuitry to determine settings for an injection-locked oscillator
WO2015143447A2 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
WO2017044840A1 (en) 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population
CN114805211A (zh) 2017-03-21 2022-07-29 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
WO2023212289A1 (en) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658966A (en) 1969-09-15 1972-04-25 Kowa Co Methods of treating hypertension
US3920833A (en) 1974-08-08 1975-11-18 Stanley Drug Products Inc Antifibrinolytic agents
US4255448A (en) 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4657704A (en) 1982-09-08 1987-04-14 Mitsui Toatsu Chemicals, Incorporated Production of aminoalkylsulfonic acids
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JP2642198B2 (ja) * 1989-08-24 1997-08-20 元庸 村上 胃粘膜障害治療剤
US5164295A (en) 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
GB9117716D0 (en) 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
AU664710B2 (en) 1991-08-27 1995-11-30 Upjohn Company, The A method for treatment of metabolic disorders
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
EP1060750B1 (en) * 1993-03-29 2005-12-07 Queen's University At Kingston Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
JPH07223970A (ja) 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
WO1995028963A1 (fr) 1994-04-22 1995-11-02 Yamanouchi Pharmaceutical Co., Ltd. Systeme de liberation de medicament specifique au colon
US5683718A (en) * 1995-04-04 1997-11-04 Time-Cap Labs, Inc. Enteric coated tablet with raised identification character and method of manufacture
CA2229427A1 (en) 1995-09-12 1997-03-20 The General Hospital Corporation Method for early detection of ovarian cancer
AU703540B2 (en) 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
EP1054664B1 (en) * 1998-02-11 2012-08-08 BHI Limited Partnership Method for modulating macrophage activation
US20020022657A1 (en) 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
EP1077690A1 (en) * 1998-05-15 2001-02-28 Neurochem, Inc. Use of amyloid inhibitors for modulating neuronal cell death
US6310073B1 (en) 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
AU4282400A (en) * 1999-04-28 2000-11-10 Neurochem (International) Limited Compositions and methods for treating amyloidosis
WO2001003680A2 (en) 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
EP1225880A2 (en) * 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
WO2001085093A2 (en) * 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
US6376557B1 (en) 2000-03-16 2002-04-23 Chanda Bhuwalka Zaveri Methods for treating alopecia
FR2832928B1 (fr) 2001-11-30 2004-02-06 Dermo Cosmologie Lab De Composition a base d'ester de diosgenine applicable par voie topique
EP1459764A4 (en) 2001-12-26 2006-08-16 Takeda Pharmaceutical REMEDIES AGAINST LIGHT COGNITIVE DISORDERS
EP1585520A1 (en) * 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US7253306B2 (en) 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20050215562A1 (en) 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050038000A1 (en) 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
PL3851447T3 (pl) 2006-10-12 2024-03-04 Bellus Health Inc. Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy

Also Published As

Publication number Publication date
CN103550196A (zh) 2014-02-05
US8835500B2 (en) 2014-09-16
AU2004248995B2 (en) 2010-01-07
PT1635799E (pt) 2009-09-23
SI1635799T1 (sl) 2009-12-31
JP4903561B2 (ja) 2012-03-28
JP2007518672A (ja) 2007-07-12
CA2529268A1 (en) 2004-12-29
EP2127648A1 (en) 2009-12-02
WO2004112762A2 (en) 2004-12-29
AU2004248995A1 (en) 2004-12-29
NZ544685A (en) 2009-05-31
DK1635799T3 (da) 2009-11-23
AU2010201299A1 (en) 2010-04-22
WO2004112762A3 (en) 2005-06-02
US20050142191A1 (en) 2005-06-30
EP1635799B1 (en) 2009-08-05
ATE438391T1 (de) 2009-08-15
US20090182056A1 (en) 2009-07-16
EP1635799A2 (en) 2006-03-22
DE602004022408D1 (de) 2009-09-17
ES2328818T3 (es) 2009-11-18
IL172193A0 (en) 2009-02-11
BRPI0411808A (pt) 2006-08-08
PL1635799T3 (pl) 2010-01-29
CA2529268C (en) 2013-10-29

Similar Documents

Publication Publication Date Title
IL172193A0 (en) Pharmaceutical formulations of amyloid inhibiting compounds
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
TW200626159A (en) Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
WO2004026246A3 (en) Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
PL1765388T3 (pl) Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu
WO2007069073A3 (en) Pharmaceutical formulations of amyloid inhibiting compounds
TW200626141A (en) Crystalline form of a drug
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
IL178120A0 (en) Therapeutic combination for treatment of alzheimers disease
ATE366720T1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
TWI349549B (en) Medicament for treatment of intraocular angiopoietic disease
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
EP1490048A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF RESPIRATORY DISEASES
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
GB0325259D0 (en) Therapeutic agents for the treatment of bone conditions

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status
GB Transfer or rights